Courses Keep Industry, Government Scientists Competitive

This past March, more than two dozen scientists gathered in a small conference room at Merck Sharp & Dohme Research Laboratories (MSDRL) in West Point, Pa. They were there for a half-day seminar on the signal transduction of receptors, the first in a five-part, company-sponsored lecture series on receptors. The instructor, Ben Margolis, an assistant professor in the department of pharmacology at New York University Medical Center, told his audience he wanted the talk to be informal--and it was.

Written byLinda Marsa
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

"He encouraged us to interrupt if we had any questions--and we all took full advantage," says Jacqueline Gress, a chemist with MSDRL who attended the lecture. "Unlike a typical college seminar, there was a lot of give-and-take. This made some very complicated scientific concepts much more accessible, and it really shortened my learning curve. The journals are flooded with so many new studies about receptors that it's virtually impossible to keep up--especially when you're working 50 or 60 hours a week. That's why this was so invaluable."

Each year, Merck sponsors dozens of on-site scientific training programs for its staffers. The pharmaceutical firm does not keep statistics on how much of this money is earmarked specifically for funding its scientifically oriented seminars on such subjects as laboratory techniques, technical writing, cell biology, immunology, pharmacology, chemical reaction mechanisms, monoclonal antibodies, and molecular biology. But the company's commitment to science education has ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies